Login / Signup

Risk factors for anti-drug antibody formation to infliximab: Secondary analyses of a randomised controlled trial.

Marthe Kirkesaether BrunGuro Løvik GollKristin Kaasen JørgensenJoseph SextonJohanna Elin GehinØystein SandangerInge Christoffer OlsenRolf Anton KlaasenDavid John WarrenCato MørkTore K KvienJørgen JahnsenNils BolstadEspen A HaavardsholmSilje Watterdal Syversen
Published in: Journal of internal medicine (2022)
Several risk factors for ADAb formation during early-phase infliximab treatment were identified. This knowledge provides a basis for treatment strategies to mitigate the formation of ADAb and identify patients in whom these measures are of particular importance.
Keyphrases
  • end stage renal disease
  • ejection fraction
  • newly diagnosed
  • chronic kidney disease
  • healthcare
  • peritoneal dialysis
  • prognostic factors
  • ulcerative colitis
  • patient reported outcomes
  • smoking cessation